New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug
19:16 EST 23 Jan 2013 | Elsevier Business Intelligence
New Zealand's Pharmac said the drug-coverage agency is weighing the $421,000-a-year cost against the benefits of subsidizing Alexion's Soliris (eculizumab) in treating to a rare type of hemophilia.
Original Article: New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug
More From BioPortfolio on "New Zealand's Pharmac Willing To Talk Price For Orphan-Hemophilia Drug"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
